CA2305414A1 - Aryl thiophene derivatives as pde iv inhibitors - Google Patents

Aryl thiophene derivatives as pde iv inhibitors Download PDF

Info

Publication number
CA2305414A1
CA2305414A1 CA002305414A CA2305414A CA2305414A1 CA 2305414 A1 CA2305414 A1 CA 2305414A1 CA 002305414 A CA002305414 A CA 002305414A CA 2305414 A CA2305414 A CA 2305414A CA 2305414 A1 CA2305414 A1 CA 2305414A1
Authority
CA
Canada
Prior art keywords
optionally substituted
3alkyl
hydrogen
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002305414A
Other languages
English (en)
French (fr)
Inventor
Yongxin Han
Dwight Macdonald
Andre Giroux
Robert N. Young
Helene Perrier
Carole Lepine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808109.4A external-priority patent/GB9808109D0/en
Application filed by Individual filed Critical Individual
Publication of CA2305414A1 publication Critical patent/CA2305414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002305414A 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors Abandoned CA2305414A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6091497P 1997-10-03 1997-10-03
US60/060,914 1997-10-03
GB9808109.4 1998-04-16
GBGB9808109.4A GB9808109D0 (en) 1998-04-16 1998-04-16 Aryl thiophene derivatives as pde iv inhibitors
PCT/CA1998/000931 WO1999018099A1 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors

Publications (1)

Publication Number Publication Date
CA2305414A1 true CA2305414A1 (en) 1999-04-15

Family

ID=26313480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002305414A Abandoned CA2305414A1 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors

Country Status (5)

Country Link
EP (1) EP1019399A1 (ja)
JP (1) JP3409029B2 (ja)
AU (1) AU732406B2 (ja)
CA (1) CA2305414A1 (ja)
WO (1) WO1999018099A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002226464A (ja) * 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd トリアリール類縁体およびその利用
WO2002083667A2 (en) * 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2003027100A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
JP4331951B2 (ja) * 2002-08-30 2009-09-16 富士フイルム株式会社 新規化合物、およびそれを用いた光学要素
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
CN101429189B (zh) * 2008-12-24 2014-07-23 沈阳药科大学 2，3-二取代芳基噻吩类衍生物及其用途
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PL2435432T6 (pl) * 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Środki wywołujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
ME02598B (me) 2011-02-07 2017-06-20 Scipharm Sarl Nova kompozicija za lečenje cistične fibroze
CA2911453C (en) 2013-05-07 2021-08-03 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
MY176814A (en) 2013-08-08 2020-08-21 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531497A (en) * 1967-02-21 1970-09-29 Upjohn Co 2,4,5 - triphenyl - (and substituted triphenyl) - 3 - acetonitriles of pyrrole
GB1271082A (en) * 1968-05-07 1972-04-19 Wyeth John & Brother Ltd Furan, pyrrole and thiophene derivatives
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
EP0318066B1 (en) * 1987-09-22 1992-07-29 Merck & Co. Inc. Aryl-substituted thiophene 3-ols, derivatives and analogs, as lipoxygenase inhibitors
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH06135961A (ja) * 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk 新規ジフェニルピロリルフラン誘導体
FR2730996B1 (fr) * 1995-02-23 1997-06-20 Adir Nouveaux composes du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
JPH11228535A (ja) * 1995-05-30 1999-08-24 Tsumura & Co 新規化合物および抗皮膚炎剤
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica

Also Published As

Publication number Publication date
AU732406B2 (en) 2001-04-26
EP1019399A1 (en) 2000-07-19
JP3409029B2 (ja) 2003-05-19
WO1999018099A1 (en) 1999-04-15
AU9334798A (en) 1999-04-27
JP2001519347A (ja) 2001-10-23
WO1999018099B1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
US6034089A (en) Aryl thiophene derivatives as PDE IV inhibitors
CA2305413A1 (en) Aryl furan derivatives as pde iv inhibitors
DE69706642T2 (de) Pyridylfuran- und Pyridylthiphenderivate und deren pharmazeutische Verwendung
EP0770065B1 (en) Tri-substituted phenyl derivates useful as pde iv inhibitors
US7115591B2 (en) Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US5710170A (en) Tri-aryl ethane derivatives as PDE IV inhibitors
EP0863891B1 (en) (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
US5698584A (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
EP0904269B1 (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6057319A (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
KR20110038159A (ko) 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
CA2364653A1 (en) Pde iv inhibiting compounds, compositions and methods of treatment
CA2305414A1 (en) Aryl thiophene derivatives as pde iv inhibitors
CA2238875C (en) Tri-aryl ethane derivatives as pde iv inhibitors
AU2013291865A1 (en) Thiophene derivatives used in the treatment of diabetes
JPH0971586A (ja) 新規な二環性縮合イミダゾール誘導体
CA2340230C (en) Pyridazinone derivatives having cell adhesion inhibiting activity
KR100675028B1 (ko) 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제로서의 아릴피리다지논, 이를 포함하는 약제학적 조성물 및 이의 제조방법
CA2239053C (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
AU711902C (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead